Generation Bio Co.

NasdaqGS:GBIO Rapporto sulle azioni

Cap. di mercato: US$178.2m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Generation Bio Gestione

Gestione criteri di controllo 3/4

Generation Bio's Il CEO è Geoff McDonough, nominato in Oct2017, e ha un mandato di 6.83 anni. la retribuzione annua totale è $ 2.32M, composta da 27.2% di stipendio e 72.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.75% delle azioni della società, per un valore di $ 4.59M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.3 anni e 6.7 anni.

Informazioni chiave

Geoff McDonough

Amministratore delegato

US$2.3m

Compenso totale

Percentuale dello stipendio del CEO27.2%
Mandato del CEO6.8yrs
Proprietà del CEO2.7%
Durata media del management3.3yrs
Durata media del Consiglio di amministrazione6.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

May 01
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Dec 07
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

Jul 11
Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Mar 11
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

Nov 19
Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Aug 05
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio GAAP EPS of -$0.66 misses by $0.04

Aug 04

Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Apr 20
Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Generation Bio: High-Risk, Medium-To-Low-Reward

Dec 30

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Nov 11
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Jul 28
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Mar 08
Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Jan 14
Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Generation Bio's insiders on buying spree, stock +4%

Jan 13

Generation Bio prices equity offering at $24.50

Jan 07

Generation Bio files to offer 7.5M shares

Jan 04

Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Dec 27
Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Generation Bio EPS misses by $0.01

Nov 10

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Geoff McDonough rispetto agli utili di Generation Bio?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$158m

Mar 31 2024n/an/a

-US$169m

Dec 31 2023US$2mUS$630k

-US$127m

Sep 30 2023n/an/a

-US$124m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$134m

Dec 31 2022US$4mUS$606k

-US$137m

Sep 30 2022n/an/a

-US$135m

Jun 30 2022n/an/a

-US$136m

Mar 31 2022n/an/a

-US$129m

Dec 31 2021US$6mUS$583k

-US$119m

Sep 30 2021n/an/a

-US$112m

Jun 30 2021n/an/a

-US$101m

Mar 31 2021n/an/a

-US$88m

Dec 31 2020US$2mUS$516k

-US$81m

Sep 30 2020n/an/a

-US$72m

Jun 30 2020n/an/a

-US$68m

Mar 31 2020n/an/a

-US$65m

Dec 31 2019US$593kUS$424k

-US$61m

Compensazione vs Mercato: La retribuzione totale di Geoff ($USD 2.32M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.54M ).

Compensazione vs guadagni: La retribuzione di Geoff è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Geoff McDonough (54 yo)

6.8yrs

Mandato

US$2,315,263

Compensazione

Dr. Cameron Geoffrey McDonough, also known as Geoff, M.D. serves as Independent Director of Third Harmonic Bio, Inc. since March 2024. He had been an Independent Director of Surface Oncology, Inc. since Fe...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Cameron McDonough
President6.8yrsUS$2.32m2.75%
$ 4.9m
Matthew Norkunas
Chief Financial Officer4.1yrsUS$1.14m0.082%
$ 146.8k
Matthew Stanton
Chief Scientific Officer5.3yrsUS$1.15m0.37%
$ 657.2k
Yalonda Howze
Chief Legal Officer & Secretary1.3yrsUS$1.21m0.018%
$ 31.6k
Mark Angelino
Co-Founder7.8yrsNessun datoNessun dato
Robert Kotin
Co-Founderno dataNessun datoNessun dato
Antoinette Paone
Chief Operating Officer2.5yrsNessun dato0.022%
$ 39.9k
Jasmin Tower
Chief Human Resources Officer1.4yrsNessun datoNessun dato
Phillip Samayoa
Chief Strategy Officer1.9yrsNessun dato0.18%
$ 323.8k

3.3yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di GBIO è considerato esperto (durata media dell'incarico 3.3 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Cameron McDonough
President6.8yrsUS$2.32m2.75%
$ 4.9m
Jason Rhodes
Independent Chairman6.8yrsUS$181.21k0%
$ 0
Gustav Christensen
Independent Director6.7yrsUS$143.71k0.20%
$ 350.9k
Charles Rowland
Independent Director6.1yrsUS$151.21k0.80%
$ 1.4m
Anthony Quinn
Independent Director6.7yrsUS$143.71k0.24%
$ 430.8k
Andrew Scharenberg
Chairman of Scientific Advisory Boardno dataNessun datoNessun dato
Donald Nicholson
Independent Director6.7yrsUS$143.71k0.32%
$ 570.3k
Kevin Fitzgerald
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Adrian Thrasher
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Ronald H. Cooper
Independent Director3.4yrsUS$144.21k0.014%
$ 25.4k
Catherine Stehman-Breen
Independent Director6.7yrsUS$143.71k0.071%
$ 126.9k
Richard Thompson
Member of Scientific Advisory Board5.8yrsNessun datoNessun dato

6.7yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GBIO sono considerati esperti (durata media dell'incarico 6.7 anni).